Azitra Inc Quick Ratio (AZTR) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Azitra Inc   (NYSEAMER: AZTR)

Azitra Inc 's Quick Ratio

AZTR's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the second quarter 2026, Quick Ratio deteriorated to 4.4 above company average Quick Ratio.

Within Major Pharmaceutical Preparations industry 195 other companies have achieved higher Quick Ratio than Azitra Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 506 to 872.

Explain Quick Ratio?
How much Cash & cash equivalents AZTR´s has?
What are AZTR´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

AZTR Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 5.39 % 21.04 % -22.38 % 32.02 % -16.49 %
Y / Y Cash & cash equivalent Change 543.36 % 213.44 % -54.59 % -80.69 % 30.21 %
Quick Ratio MRQ 4.4 6.49 1.94 0.78 0.72
AZTR's Total Ranking # 872 # 506 # 891 # 1736 # 1654
Seq. Current Liabilities Change -1.23 % 45.11 % -40.87 % 24.35 % 13.43 %
Seq. Cash & cash equivalent Change -33.06 % 386.01 % 47.52 % 34.06 % -67.39 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 196
Healthcare Sector # 330
Overall Market # 872


Quick Ratio Statistics
High Average Low
6.49 2.71 0.46
(Mar 31 2026)   (Jun 30 2024)




Financial Statements
Azitra Inc 's Current Liabilities $ 2 Millions Visit AZTR's Balance sheet
Azitra Inc 's Cash & cash equivalent $ 7 Millions Visit AZTR's Balance sheet
Source of AZTR's Sales Visit AZTR's Sales by Geography


Cumulative Azitra Inc 's Quick Ratio

AZTR's Quick Ratio for the trailling 12 Months

AZTR Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 8.73 % 1.96 % -2.33 % -0.89 % -9.53 %
Y / Y Cash & cash equivalent TTM Growth 26.02 % -7.95 % -50.56 % -20.62 % 60.66 %
Quick Ratio TTM 3.4 2.48 1.38 1.73 2.93
Total Ranking TTM # 3696 # 3016 # 2493 # 3069 # 2805
Seq. Current Liabilities TTM Growth 1.33 % 4.8 % -5.21 % 8 % -4.97 %
Seq. Cash & cash equivalent TTM Growth 39.01 % 88.63 % -24.36 % -36.46 % 1.53 %

Quick ratio ranking by company, industry and sector >> Back to AZTR Financial Strength Comparisons >> Go to Compare AZTR Quick Ratio to its Competitors

On the trailing twelve months basis AZTR Cash & cash equivalent more than doubled by 543.36 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Azitra Inc 's Quick Ratio to 3.4, above AZTR average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 427 other companies have achieved higher Quick Ratio than Azitra Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3016 to 3696.

Explain Quick Ratio?
How much Cash & cash equivalents AZTR´s has?
What are AZTR´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 428
Healthcare Sector # 870
Within the Market # 3696


trailing twelve months Quick Ratio Statistics
High Average Low
3.4 2.37 1.38
(Jun 30 2026)   (Dec 31 2025)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Wave Life Sciences Ltd   12.07 $ 613.194  Millions$ 50.815  Millions
Amylyx Pharmaceuticals Inc   11.86 $ 250.760  Millions$ 21.150  Millions
Moonlake Immunotherapeutics  11.83 $ 537.000  Millions$ 45.392  Millions
Eledon Pharmaceuticals Inc   11.77 $ 170.753  Millions$ 14.503  Millions
Tyra Biosciences Inc   11.76 $ 354.060  Millions$ 30.106  Millions
Opus Genetics Inc   11.69 $ 88.912  Millions$ 7.605  Millions
Aardvark Therapeutics Inc   11.57 $ 73.921  Millions$ 6.387  Millions
Dyne Therapeutics Inc   11.51 $ 898.475  Millions$ 78.029  Millions
Evommune Inc   11.50 $ 201.014  Millions$ 17.487  Millions
Bicara Therapeutics Inc   11.44 $ 497.259  Millions$ 43.475  Millions
Lipocine Inc   11.25 $ 23.267  Millions$ 2.068  Millions
Xenon Pharmaceuticals Inc   10.85 $ 930.686  Millions$ 85.795  Millions
Bicycle Therapeutics Plc  10.71 $ 510.052  Millions$ 47.635  Millions
Entrada Therapeutics Inc   10.44 $ 223.112  Millions$ 21.371  Millions
Vera Therapeutics Inc   10.33 $ 499.161  Millions$ 48.321  Millions
Ideaya Biosciences Inc   10.03 $ 828.955  Millions$ 82.677  Millions
Gri Bio Inc   9.95 $ 10.947  Millions$ 1.100  Millions
Renovorx Inc   9.86 $ 18.579  Millions$ 1.884  Millions
Savara Inc   9.83 $ 173.034  Millions$ 17.599  Millions
Bullfrog Ai Holdings Inc   9.79 $ 6.918  Millions$ 0.707  Millions
Enveric Biosciences Inc   9.63 $ 8.296  Millions$ 0.861  Millions
Pliant Therapeutics Inc   9.62 $ 158.500  Millions$ 16.484  Millions
Rezolute Inc   9.44 $ 107.801  Millions$ 11.418  Millions
Crescent Biopharma Inc   9.26 $ 171.593  Millions$ 18.537  Millions
Marker Therapeutics inc   9.10 $ 22.031  Millions$ 2.420  Millions
Synlogic Inc   9.03 $ 13.200  Millions$ 1.461  Millions
Spruce Biosciences Inc   8.78 $ 96.300  Millions$ 10.963  Millions
Newamsterdam Pharma Company N v   8.69 $ 633.854  Millions$ 72.974  Millions
Medicinova Inc   8.58 $ 25.416  Millions$ 2.961  Millions
Lixte Biotechnology Holdings Inc   8.45 $ 12.670  Millions$ 1.500  Millions

Date modified: 2026-09-12T06:26:59+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.